Sertraline for Anxiety Disorders

Efficacy and Mechanism

The American Academy of Child and Adolescent Psychiatry recommends sertraline for the treatment of anxiety disorders, including social anxiety disorder, generalized anxiety disorder, separation anxiety, and panic disorder, based on substantial empirical evidence supporting its effectiveness and safety 1, 2, 3
Sertraline belongs to the selective serotonin reuptake inhibitor (SSRI) class, which has been shown to improve primary anxiety symptoms, response to treatment, remission rates, and global functioning compared to placebo 1, 3
Sertraline inhibits the presynaptic reuptake of serotonin in the brain, increasing serotonin availability at the synaptic cleft, and is believed to play a key role in modulating fear, worry, and stress responses, as well as facilitating cognitive processing of emotions 1, 3

The therapeutic effect of sertraline typically follows a logarithmic model, with statistically significant improvement within 2 weeks, clinically significant improvement by week 6, and maximal improvement by week 12 or later 4, 5
A conservative approach for mild to moderate anxiety includes starting with a subtherapeutic "test" dose, increasing the dose at 1-2 week intervals in small increments, and titrating until optimal benefit-to-harm ratio is achieved 5, 6, 7

Common side effects of sertraline may include gastrointestinal symptoms, headache, somnolence, insomnia, dizziness, and changes in appetite or weight 2, 4
More serious but less common adverse effects include serotonin syndrome, particularly when combined with other serotonergic medications 7

Combining sertraline with cognitive behavioral therapy (CBT) has shown superior outcomes compared to either treatment alone for children and adolescents with anxiety disorders 5, 6
For adults with social anxiety disorder, both SSRIs and CBT are recommended treatment options, though there is insufficient evidence to make a definitive recommendation regarding combination therapy 8, 9